AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25526014
Drug: Fit Minded
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fit Minded Tablet (n=15)
Trial: 24030535
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyaluronic acid (HA) and tamarind seed polysaccharide (TS‐polysaccharide)
Trial: 19954391
Drug: Methylprednisolone aceponate
RxNorm normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone aceponate 0.1% cream
Trial: 10773104
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate therapy (400 mg/day for 14 days every 3 months) followed by 500 mg/day of elemental calcium for 1 year
Trial: 10773104
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by 500 mg/day of elemental calcium for 1 year
Trial: 8643695
Drug: Cladribine 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine 0.10 mg/kg per day for 7 days as four monthly courses (total 2.8 mg/kg)
Trial: 8643695
Drug: Cladribine i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine i.v. infusions of 0.10 mg, 0.05 mg, and 0.05 mg per kg of body weight per day for 7 consecutive days in three successive monthly courses (total 1.4 mg/kg)
Trial: 26087884
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise intervention (cycling for at least 15 minutes daily for 15 months)
Trial: 20739450
Drug: Almond skin
RxNorm normalized name: Bodi Line Almond Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond skin phenolic extract (884 mg of total polyphenols/dose)
Trial: 16463656
Drug: L-carnitine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (12 g/L in ST. Thomas cardioplegia)
Trial: 11996470
Drug: Schedule A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Trial: 11996470
Drug: Schedule B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule B (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Trial: 7655177
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hip axis length and bone mineral density
Trial: 7655177
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Singh grade, hip axis length, and bone mineral density
Trial: 2119677
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tenoxicam once daily for 8 days (days 5-12)
Trial: 2119677
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg glibenclamide once daily for 12 days
Trial: 2119677
Drug: Mean oral
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean oral clearance of tenoxicam
Trial: 26034367
Drug: Modified sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified sequential therapy (Group B): ilaprazole at 5 mg bid, amoxicillin and clavulanate potassium at 914 mg for the first five days, followed by ilaprazole at 5 mg bid, furazolidone at 100 mg bid, and levofloxacin at 500 mg qid for the next five days.
Trial: 26034367
Drug: Standard quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard quadruple therapy (Group A): ilaprazole + bismuth potassium citrate + amoxicillin and clavulanate potassium + levofloxacin.
Trial: 17420159
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil (two enteric-coated capsules twice per day)
Trial: 15815889
Drug: Inpatient topical
RxNorm normalized name: Impatiens balsamina flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient topical treatment with dithranol and narrow band UV‐B 311 nm
Trial: 15815889
Drug: Biologics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics treatment with efalizumab
Trial: 11964576
Drug: High-volume preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume preparation of botulinum toxin-A (60 units)
Trial: 11964576
Drug: Low-volume preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume preparation of botulinum toxin-A (60 units)
Trial: 8749612
Drug: Physostigmine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine administered by steady-state, continuous intravenous infusion
Trial: 2677915
Drug: Conservative functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative functional treatment
Trial: 29699717
Drug: Telephone referral
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone referral from Primary Health Care to Internal Medicine Consult
Trial: 29699717
Drug: Traditional referral
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional referral from Primary Health Care to Internal Medicine Consult
Trial: 19491016
Drug: (99m)Tc-NC100692, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc-NC100692, intravenous injection of 150 micrograms
Trial: 16982293
Drug: Meropenem 500
RxNorm normalized name: meropenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 500 mg intravenously every 8 hours
Trial: 16982293
Drug: Imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 500 mg intravenously every 8 hours
Trial: 15579755
Drug: Androstenedione (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androstenedione (100 mg)
Trial: 8361987
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg regular aspirin daily (14 pills)
Trial: 8361987
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg regular aspirin daily (14 pills)
Trial: 8361987
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg enteric-coated aspirin daily (14 pills)
Trial: 8361987
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg regular aspirin every other day (7 pills)
Trial: 8361987
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg daily aspirin
Trial: 3791663
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg p.o. at 2200 and 2400 h)
Trial: 29388085
Drug: Intra-articular combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular combined with intraosseous injection of PRP (administered twice, 2 weeks apart)
Trial: 29388085
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of PRP (every 14 days)
Trial: 29388085
Drug: Intra-articular HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular HA (five injections every 7 days)
Trial: 26928796
Drug: Control (Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Intravenous saline infusion)
Trial: 24132867
Drug: manualized dialectical-behavioral-therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus methylphenidate (MPH)
Trial: 24132867
Drug: manualized dialectical-behavioral-therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus placebo (Plac)
Trial: 20670909
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of virosomal-adjuvanted influenza vaccine (two doses of 0.50 mL 4 weeks apart)
Trial: 20670909
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of virosomal-adjuvanted influenza vaccine (two doses of 0.25 mL 4 weeks apart)
Trial: 12063152
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) for 38 weeks followed by 12 weeks of placebo
Trial: 12063152
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) for 14 weeks followed by 36 weeks of placebo
Trial: 2245435
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg od
Trial: 2245435
Drug: Gemfibrozil, 600
RxNorm normalized name: Gemfibrozil, 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil, 600 mg bid
Trial: 32861
Drug: Melperone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone (100 mg X 3)
Trial: 32861
Drug: Thiothixene (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiothixene (10 mg X 3)
Trial: 30327398
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) after standard chemotherapy, delivered in 15 fractions of 3-4.5 Gy.
Trial: 30327398
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) after standard chemotherapy
Trial: 21787207
Drug: Low-dose acitretin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acitretin (approximately 25 mg/day)
Trial: 21787207
Drug: High-dose acitretin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acitretin (approximately 50 mg/day)
Trial: 12575301
Drug: Dengzhanhua injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengzhanhua injection (Group A)
Trial: 12575301
Drug: Fufangdanshen injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufangdanshen injection (Group B)
Trial: 6420046
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum and chemotherapy (C + I)
Trial: 20486208
Drug: Hop intervention
RxNorm normalized name: HOPS
DrugBank: Hops (DB10687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hop intervention (2.04 mg XN, 1.20 mg IX, and 0.1 mg 8‐PN per supplement)
Trial: 20486208
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hop supplements)
Trial: 11807724
Drug: AC polysaccharide
RxNorm normalized name: meningococcal AC polysaccharide (non-US)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC polysaccharide (MACP) vaccine
Trial: 11807724
Drug: C conjugate
RxNorm normalized name: meningococcal C conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C conjugate (MCC) vaccine
Trial: 10417495
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 mg twice daily)
Trial: 1914366
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg aspirin with 64 mg caffeine
Trial: 6312791
Drug: Soy polysaccharide
RxNorm normalized name: Soy polysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy polysaccharide (25 g/day)
Trial: 6312791
Drug: Soy polysaccharide
RxNorm normalized name: Soy polysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy polysaccharide added to glucose solution
Trial: 25100134
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/day on a 4-week-on-2-week-off schedule
Trial: 25100134
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/day continuous dosing
Trial: 11049006
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g x kg(‐1) ethanol (EOH) in young subjects
Trial: 11049006
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg diazepam (DZ) in young subjects
Trial: 11049006
Drug: 0.7 g
RxNorm normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g x kg(‐1) ethanol (EOH) in older subjects
Trial: 11049006
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam (DZ) in older subjects
Trial: 9313702
Drug: lexipafant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lexipafant (100 mg/day by continuous intravenous infusion for up to 7 days)
Trial: 12959281
Drug: Frusemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (40 mg oral dose)
Trial: 28920183
Drug: Regularly prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regularly prescribed medications (average 5.6 medications per patient)
Trial: 28920183
Drug: CIRS-G index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIRS-G index measures
Trial: 28920183
Drug: Polypharmacy (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (defined as five or more concurrent medications)
Trial: 26588662
Drug: Cabozantinib 40
RxNorm normalized name: cabozantinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 40 mg daily with RT plus TMZ and post-RT TMZ
Trial: 23553848
Drug: Cabozantinib 40
RxNorm normalized name: cabozantinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 40 mg daily
Trial: 26588662
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment arm
Trial: 19229603
Drug: ivabradine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine therapy initiated at the time of hospital admission
Trial: 15046281
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition admixtures exposed to ambient light for 24 hours
Trial: 15046281
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition admixtures protected from ambient light for 24 hours
Trial: 11913007
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly sessions about healthy eating followed by 6 weekly sessions about exercise
Trial: 11913007
Drug: 6 weekly
RxNorm normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weekly sessions about exercise followed by 10 weekly sessions about healthy eating
Trial: 9522325
Drug: High-levonorgestrel group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.25 mg levonorgestrel (days 12-21)
Trial: 9522325
Drug: Low-levonorgestrel group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.15 mg levonorgestrel (days 10-21)
Trial: 3117490
Drug: NORPLANT implants
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NORPLANT implants (first set)
Trial: 3117490
Drug: NORPLANT implants
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NORPLANT implants (replacement set)
Trial: 11225746
Drug: Buffered regular
RxNorm normalized name: INSULIN,REGULAR,HUMAN BUFFERED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered regular human insulin (Velosulin)
Trial: 1444555
Drug: 5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml/kg 20% albumin
Trial: 1444555
Drug: 15 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml/kg 4.5% albumin
Trial: 1444555
Drug: 15 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml/kg fresh frozen plasma
Trial: 29727479
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 0.4 mg/kg per week
Trial: 29727479
Drug: Ciclosporin (CyA)
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin (CyA) 4 mg/kg per day
Trial: 25237463
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg (group A)
Trial: 25237463
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg and solifenacin 5 mg (group B)
Trial: 19508590
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (NP) infusion
Trial: 19508590
Drug: Forearm balance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm balance of nitric oxide (NO) during ACh infusion
Trial: 18229580
Drug: Steroid and
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid and Xueshuantong
Trial: 18229580
Drug: Steroid, DF‐521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid, DF‐521 and Xueshuantong
Trial: 8765697
Drug: Indomethacin hard-gelatin
RxNorm normalized name: Hard Gelatin Capsule Shell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin hard-gelatin capsule with saturated polyglycolysed glycerides (Gelucire)
Trial: 8765697
Drug: Standard multiple-unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multiple-unit diffusion-controlled pellet capsule (reference formulation)
Trial: 173814
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy alone (22 patients)
Trial: 173814
Drug: Combined radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiation and drug therapy (19 patients)
Trial: 27609785
Drug: 23/25 G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23/25 G vitrectomy without any buckle (group E2)
Trial: 15006955
Drug: Moxifloxacin (MXF),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (MXF), 400 mg
Trial: 15006955
Drug: Levofloxacin (LEVO),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (LEVO), 500 mg daily for five doses
Trial: 15006955
Drug: Azithromycin (AZI),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (AZI), 500 mg for one dose, then 250 mg daily for four doses
Trial: 3707653
Drug: Ibopamine 50
RxNorm normalized name: ibopamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 50 mg t.i.d.
Trial: 3358887
Drug: Vigabatrin 1
RxNorm normalized name: vigabatrin 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 1 g
Trial: 3358887
Drug: Vigabatrin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 2 g
Trial: 3358887
Drug: Vigabatrin 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 4 g
Trial: 3358887
Drug: Vigabatrin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 2 g daily for 6 weeks
Trial: 3358887
Drug: Vigabatrin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 3 g daily for 6 weeks
Trial: 3358887
Drug: Post-treatment (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (1 week after stopping vigabatrin)
Trial: 23253948
Drug: empagliflozin 50
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: empagliflozin 50 mg q.d. for 5 days with metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Trial: 23253948
Drug: metformin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Trial: 21727662
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (75 mg/day for 12 weeks)
Trial: 16490805
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg aprepitant capsule on day 1 followed by 80 mg on days 2 and 3
Trial: 16490805
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg and 80 mg aprepitant capsules administered in fed vs. fasted state
Trial: 16490805
Drug: 3-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day regimen of aprepitant (125 mg/80 mg/80 mg)
Trial: 12721261
Drug: No endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endocrine therapy
Trial: 12721261
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment (Goserelin or Tamoxifen)
Trial: 10714571
Drug: COL-1492 (52.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL-1492 (52.5 mg N-9 gel)
Trial: 1303479
Drug: Cefoperazone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (1 gm per dose for 24 hours)
Trial: 1303479
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg per dose for 24 hours)
Trial: 3919746
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of lysine acetyl salicylate (LAS)